SLC5A2 and type 1 diabetes mellitus: In addition, the study durations of these RCTs (with a maximum of 52 weeks) might have been too short to evaluate the additional non-glycemic benefits of SGLT2 inhibitors in T1D [5,6,7,8,9,10,11,12,13,14].